Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study.

ABSTRACT:

SUBMITTER: Hutter-Kronke ML 

PROVIDER: S-EPMC6355481 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature